Drug Profile
Recombinant lubricin - Lubris BioPharma/Novartis
Alternative Names: ECF 843; lubricin recombinant; rh-lubricinLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Lubris BioPharma
- Developer Dompe Farmaceutici; Lubris BioPharma; Novartis
- Class Antirheumatics; Eye disorder therapies; Glycoproteins; Recombinant proteins
- Mechanism of Action Lubricin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Dry eyes
- No development reported Osteoarthritis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Osteoarthritis in USA
- 26 Jul 2021 Preclinical development is ongoing for osteoarthritis in the US (Lubris Biopharma website, July 2021)
- 25 May 2021 Novartis completes Phase-II clinical trials in Dry eyes in USA (Ophthalmic) (NCT04391894)